Abstract
Background and Aims
Flash glucose monitoring (FGM) allows non-invasive glucose level assessment. Studies have shown that patients using FGM test their glucose levels more often than those who use traditional blood glucose testing. Our objective was to describe the change in the glycemic control expressed as HbA1c and time in euglycemic range (70-180 mg/dL), above range and below range in patients with type 1 diabetes (DM1) after FGM implementation and the effect of the number of scans in this control.
Methods
Observational longitudinal clinical study between June 2018 and September 2019 in patients with DM1 and subsidized FGM implementation
Results
115 patients included. Mean age: 16.30 ± 1.15 years. Mean DM1 evolution time: 6.41 ± 4.59 years. 44.3% women. 47% had used FGM before it was subsidized. 4 patients decided not to use FGM anymore.
In patients with more than 70% FGM data, one year after implementation estimated HbA1c levels were reduced from 7.47% to 7.09% but this was not statistically significant.
After 1 year, time in range (TIR) was higher and time in hypoglycemia (Hypo) was reduced the more daily scans (DS) patients performed. (TIR = 1.50 ·DS + 39.88; R2 = 21,1%. Hypo = -1.54·DS + 50.77; R2=16,7%; p<0.01). However, time in hyperglycemia didn’t show a significative reduction.
Conclusions
In our series, FGM implementation reduced HbA1c levels and the time patients spent in hyperglycemia, although it was not statistically significant.
The more scans performed the more time patients spent in range and the less time in hypoglycemia (p<0.01). This improvement wasn’t seen in time in hyperglycemia.
